Results 61 to 70 of about 23,498 (195)
A Representative Survey of M.S. Patients on Attitudes toward the Benefits and Risks of Drug Therapy [PDF]
, 2006 Background: Although M.S. patients face significant trade-offs between risks and benefits of drug therapy, little is known of their attitudes toward these risks and benefits.
John E. Calfee
core
Clinical Pharmacology &Therapeutics, EarlyView.There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh +4 more
wiley +1 more source
Relapsing-remitting multiple sclerosis: advances in disease-modifying therapies [PDF]
, 2015 Multiple sclerosis is a demyelinating disease affecting the central nervous system. It is the most prevalent disabling neurological condition among young adults, with onset typically between 20 and 40 years of age. Infiltrating immune cells and microglia
Kay, Kathleen Alexandra
core +1 more source
Role of subclinical gut inflammation in the pathogenesis of spondyloarthritis [PDF]
, 2018 Subclinical gut inflammation occurring in patients affected by spondyloarthritis (SpA) is correlated with the severity of spine inflammation. Several evidences indicate that dysbiosis occurs in SpA, and that may modulate intestinal permeability and ...
Ciccia F. +3 more
core +1 more source
Therapeutic Advances in Neurological Disorders, 2018 Background: Natalizumab significantly reduces the disease activity in patients with relapsing-remitting multiple sclerosis but due to the risk of progressive multifocal leukoencephalopathy it is often discontinued.
Lara Diem +4 more
doaj +1 more source
Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.Abstract Objectives Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real‐world clinical settings for children with CD. Methods Data were collected from the prospective ImproveCareNow (ICN) registry for pediatric patients (≥ 2 to <18 years old)
Steven J. Steiner +60 more
wiley +1 more source
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 5, May 2026.ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein +8 more
wiley +1 more source
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group [PDF]
, 2015 The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influenced by the occurrence of progressive multifocal leukoencephalopathy (PML).
Craner, M +10 more
core +1 more source
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
Case Reports in Neurological Medicine, 2014 Background. Natalizumab treatment is frequently discontinued and replaced by alternative medication in multiple sclerosis (MS) patients having a high risk of progressive multifocal leukoencephalopathy (PML). Case Presentation.
J. Killestein +5 more
doaj +1 more source